Neumora Therapeutics, Inc. Common Stock
NMRANASDAQHealthcare● Active
$1.62
$-0.01(-0.61%)
Market Cap$300160469
P/E Ratio—
52W High$3.65
52W Low$0.716
Neumora Therapeutics, Inc. Common Stock (NMRA) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · NMRA · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($0.24B) | ($0.24B) | ($0.24B) | ($0.13B) | ($0.24B) |
| Depreciation & Amort. | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Stock-Based Comp. | $0.03B | $0.04B | $0.02B | $0.01B | $0.00B |
| Change in Working Capital | ($0.00B) | $0.02B | ($0.01B) | ($0.01B) | ($0.00B) |
| Net Cash from Operations | ($0.21B) | ($0.18B) | ($0.16B) | ($0.11B) | ($0.08B) |
| Investing Activities | |||||
| Capital Expenditure | $0.00B | $0.00B | ($0.00B) | ($0.00B) | ($0.00B) |
| Purchases of Investments | ($0.09B) | ($0.31B) | ($0.11B) | ($0.23B) | $0.00B |
| Sales of Investments | $0.25B | $0.24B | $0.18B | $0.07B | $0.00B |
| Net Cash from Investing | $0.17B | ($0.07B) | $0.06B | ($0.17B) | ($0.00B) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00B | $0.00B | ($0.00B) | $0.00B | $0.00B |
| Dividends Paid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | $0.06B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Cash from Financing | $0.08B | $0.02B | $0.23B | $0.12B | $0.29B |
| Free Cash Flow | |||||
| Free Cash Flow | ($0.21B) | ($0.18B) | ($0.16B) | ($0.12B) | ($0.08B) |
| FCF Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · B
Explore more Neumora Therapeutics, Inc. Common Stock data
About Neumora Therapeutics, Inc. Common Stock (NMRA) Cash Flow Statement
Neumora Therapeutics, Inc. Common Stock generated operating cash flow of ($0.21B) and free cash flow of ($0.21B) for 2025 — a FCF margin of —. Capital expenditure was $0.00B.
Frequently asked questions
NMRA · 4 questionsNeumora Therapeutics, Inc. Common Stock generated free cash flow of ($0.21B) for 2025, down 12.8% year-over-year.
NMRA free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10